SIAP
URGN icon

Sterling Investment Advisors (Pennsylvania)’s UroGen Pharma URGN Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$16K – 494
2022
Q2 		$16K Hold
2,000
– – 0.01% 351
2022
Q1 		$17K Hold
2,000
– – ﹤0.01% 379
2021
Q4 		$19K Hold
2,000
– – 0.01% 374
2021
Q3 		$34K Buy
+2,000
New +$31.7K 0.01% 298

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s URGN Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of UroGen Pharma (URGN) in Q3 2022, closing a stake of 2,000 shares — an estimated $16K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in URGN in Q3 2021 and held it in 4 quarters. The position peaked at $34K in Q3 2021. 60 funds tracked by Wall St. Rank hold URGN as of Q3 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining UroGen Pharma position as of Q3 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 2,000 UroGen Pharma shares in Q3 2022, an estimated $16K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in UroGen Pharma in Q3 2021 and held it in 4 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s UroGen Pharma position peaked at $34K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.